Lunaphore announces the successful installation of the COMET™ platform at Centre de Recherche des Cordeliers
LAUSANNE, Switzerland – October 25, 2022 – 5 pm (CEST) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced the installation of its COMET™ instrument at Centre de Recherche des Cordeliers (CRC), Paris. The installation of COMET™ will allow CRC researchers to identify novel predictive and mechanistic signatures that show whether patients are responding to immune checkpoint immunotherapies (ICIs), with an initial focus on non-small cell lung carcinoma (NSCLC) and colorectal cancer.
Patients with diverse tumor types have seen noticeable clinical responses with immunotherapeutic intervention, while other patients experience little to no improvement. Researchers will use COMET™ as a multiplex immunohistochemistry platform to describe the cellular composition, spatial distribution, and activity of the immune response in NSCLC and colorectal cancer. Researchers also plan to investigate interactions with major cell death pathways, such as apoptosis, pyroptosis, and necroptosis. This will allow them to better understand the toxicity linked with ICIs and find new signatures of response to these molecules.
“The cancer immunogram stemming from these targeted immunotherapies would help researchers understand the tumor immune microenvironment so that clinicians have the most accurate information possible to select the effective therapies while avoiding unnecessary toxicity associated with some ICIs,” said Ata Tuna Ciftlik, Ph.D., Chief Executive Officer of Lunaphore. “We are pleased to complete the successful installation of COMET™ at Centre de Recherche des Cordeliers and look forward to helping their scientists unlock the full potential of spatial biology.”
This latest installation of the COMET™ platform underscores Lunaphore’s leadership in the spatial biology field. The company is focused on fostering groundbreaking research with the goal of moving this revolutionary technology and the insights it provides into clinical use, where it can benefit patients’ lives in the future.
CRC hosted a Lunaphore Spatial Biology Tour™ event in October featuring expert scientists’ presentations and instrument demonstrations. Attendees had the opportunity to learn how to increase laboratory productivity while ensuring high-quality results with the next generation of spatial biology solutions and expand their network within the research community. To learn more, please visit: https://lunaphore.com/our-events/the-spatial-biology-tour-france/
To learn more about the COMET™ PA platform, please visit: https://lunaphore.com/products/comet/
To learn more about Lunaphore, please visit: https://lunaphore.com/
COMET™ is a fully automated, sequential immunofluorescence (seqIF™) instrument, able to perform hyperplex staining and imaging, producing high-quality data in a robust and reproducible manner. With superior tissue profiling capabilities, the system allows multiplex analysis of up to 40 different spatial markers per tissue slide without human intervention. COMET™ has a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology in areas such as immuno-oncology, neuroscience, and infectious diseases. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology that can extract spatial proteomic and multi-omics data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next-generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.
For further information contact:
Lunaphore Corporate Communications
Email: [email protected]